These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Pharmacologic inhibition of RGD-binding integrins ameliorates fibrosis and improves function following kidney injury. Basta J; Robbins L; Stout L; Prinsen MJ; Griggs DW; Rauchman M Physiol Rep; 2020 Apr; 8(7):e14329. PubMed ID: 32281744 [TBL] [Abstract][Full Text] [Related]
11. The first synthetic receptor for the RGD sequence. Rensing S; Schrader T Org Lett; 2002 Jun; 4(13):2161-4. PubMed ID: 12074657 [TBL] [Abstract][Full Text] [Related]
12. Strategies to inhibit tumor associated integrin receptors: rationale for dual and multi-antagonists. Sheldrake HM; Patterson LH J Med Chem; 2014 Aug; 57(15):6301-15. PubMed ID: 24568695 [TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of integrin antagonists containing trans- and cis-2,5-disubstituted THF rings. Osterkamp F; Ziemer B; Koert U; Wiesner M; Raddatz P; Goodman SL Chemistry; 2000 Feb; 6(4):666-83. PubMed ID: 10807178 [TBL] [Abstract][Full Text] [Related]
19. Platelet GPIIb/IIIa binding characteristics of small molecule RGD mimetic: distinct binding profile for Roxifiban. Mousa SA; Bozarth JM; Naik UP; Slee A Br J Pharmacol; 2001 Jun; 133(3):331-6. PubMed ID: 11375248 [TBL] [Abstract][Full Text] [Related]
20. The relative orientation of the Arg and Asp side chains defined by a pseudodihedral angle as a key criterion for evaluating the structure-activity relationship of RGD peptides. Kostidis S; Stavrakoudis A; Biris N; Tsoukatos D; Sakarellos C; Tsikaris V J Pept Sci; 2004 Aug; 10(8):494-509. PubMed ID: 15347137 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]